U.S. Markets closed

Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
14.41-0.09 (-0.62%)
At close: 4:00PM EDT

15.00 +0.59 (4.09%)
After hours: 6:04PM EDT

People also watch
Full screen
Previous Close14.50
Bid7.35 x 100
Ask14.99 x 600
Day's Range14.15 - 15.49
52 Week Range12.48 - 19.94
Avg. Volume1,176,787
Market Cap2.16B
PE Ratio (TTM)-17.40
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals11 hours ago

    Ironwood gets FDA approval for new drug for gout

    Cambridge-based Ironwood Pharmaceuticals has gotten U.S. approval to sell its treatment for a condition associated with gout, called hyperuricemia. The oral drug, called Duzallo, helps patients with the highly symptomatic and painful form of inflammatory arthritis caused by elevated levels of uric acid in the blood. The current method of treatment, a generic drug by the name of allopurinol, is able to successfully treat approximately a quarter of the 8 million patients with gout in the U.S, Ironwood’s (IRWD) new combination therapy will be able to treat about half of them.

  • 24/7 Wall St.12 hours ago

    Ironwood Pharma Muted Despite FDA Approval

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment duzallo. ...

  • TheStreet.com14 hours ago

    Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

    The Cambridge, Mass.-based firm clinched FDA approval for hyperuricemia drug Duzallo.